tetano
Editor, Senior Moderator
Clin Infect Dis
. 2024 Mar 15:ciae121.
doi: 10.1093/cid/ciae121. Online ahead of print. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Serologic Testing
Mary K Hayden[SUP] 1 [/SUP], Ibrahim K El Mikati[SUP] 2 3 [/SUP], Kimberly E Hanson[SUP] 4 [/SUP], Janet A Englund[SUP] 5 [/SUP], Romney M Humphries[SUP] 6 [/SUP], Francesca Lee[SUP] 7 [/SUP], Mark Loeb[SUP] 8 [/SUP], Daniel J Morgan[SUP] 9 [/SUP], Robin Patel[SUP] 10 [/SUP], Omar Al Ta'ani[SUP] 11 [/SUP], Jamil Nazzal[SUP] 12 [/SUP], Shahad Iqneibi[SUP] 13 [/SUP], Justin Z Amarin[SUP] 14 [/SUP], Shahnaz Sultan[SUP] 15 [/SUP], Yngve Falck-Ytter[SUP] 16 [/SUP], Rebecca L Morgan[SUP] 17 [/SUP], M Hassan Murad[SUP] 18 [/SUP], Adarsh Bhimraj[SUP] 19 [/SUP], Reem A Mustafa[SUP] 20 [/SUP]
Affiliations
Background: The role of serologic testing for SARS-CoV-2 has evolved during the pandemic as seroprevalence in global populations has increased. The Infectious Diseases Society of America (IDSA) convened an expert panel to perform a systematic review of the coronavirus disease 2019 (COVID-19) serology literature and construct updated best practice guidance related to SARS-CoV-2 serologic testing. This guideline is an update to the fourth in a series of rapid, frequently updated COVID-19 guidelines developed by IDSA.
Objective: To develop evidence-based recommendations and identify unmet research needs pertaining to the use of anti-SARS-CoV-2 antibody tests for diagnosis, decisions related to vaccination and administration of monoclonal antibodies or convalescent plasma in immunocompromised patients, and identification of a serologic correlate of immunity.
Methods: A multidisciplinary panel of infectious diseases clinicians, clinical microbiologists and experts in systematic literature reviewed, identified, and prioritized clinical questions related to the use of SARS-CoV-2 serologic tests. Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the certainty of evidence and make testing recommendations.
Results: The panel recommends against serologic testing to diagnose SARS-CoV-2 infection in the first two weeks after symptom onset (strong recommendations, low certainty of evidence). Serologic testing should not be used to provide evidence of COVID-19 in symptomatic patients with a high clinical suspicion and repeatedly negative nucleic acid amplification test results (strong recommendation, very low certainty of evidence). Serologic testing may assist with the diagnosis of multisystem inflammatory syndrome in children (strong recommendation, very low certainty of evidence). To seek evidence for prior SARS-CoV-2 infection, the panel suggests testing for IgG, IgG/IgM, or total antibodies to nucleocapsid protein three to five weeks after symptom onset (conditional recommendation, low certainty of evidence). In individuals with previous SARS-CoV-2 infection or vaccination, we suggest against routine serologic testing given no demonstrated benefit to improving patient outcomes (conditional recommendation, very low certainty of evidence.) The panel acknowledges further that a negative spike antibody test may be a useful metric to identify immunocompromised patients who are candidates for immune therapy.
Conclusions: The high seroprevalence of antibodies against SARS-CoV-2 worldwide limits the utility of detecting anti-SARS CoV-2 antibody. The certainty of available evidence supporting the use of serology for diagnosis was graded as very low to low. Future studies should use serologic assays calibrated to a common reference standard.
. 2024 Mar 15:ciae121.
doi: 10.1093/cid/ciae121. Online ahead of print. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Serologic Testing
Mary K Hayden[SUP] 1 [/SUP], Ibrahim K El Mikati[SUP] 2 3 [/SUP], Kimberly E Hanson[SUP] 4 [/SUP], Janet A Englund[SUP] 5 [/SUP], Romney M Humphries[SUP] 6 [/SUP], Francesca Lee[SUP] 7 [/SUP], Mark Loeb[SUP] 8 [/SUP], Daniel J Morgan[SUP] 9 [/SUP], Robin Patel[SUP] 10 [/SUP], Omar Al Ta'ani[SUP] 11 [/SUP], Jamil Nazzal[SUP] 12 [/SUP], Shahad Iqneibi[SUP] 13 [/SUP], Justin Z Amarin[SUP] 14 [/SUP], Shahnaz Sultan[SUP] 15 [/SUP], Yngve Falck-Ytter[SUP] 16 [/SUP], Rebecca L Morgan[SUP] 17 [/SUP], M Hassan Murad[SUP] 18 [/SUP], Adarsh Bhimraj[SUP] 19 [/SUP], Reem A Mustafa[SUP] 20 [/SUP]
Affiliations
- PMID: 38489670
- DOI: 10.1093/cid/ciae121
Background: The role of serologic testing for SARS-CoV-2 has evolved during the pandemic as seroprevalence in global populations has increased. The Infectious Diseases Society of America (IDSA) convened an expert panel to perform a systematic review of the coronavirus disease 2019 (COVID-19) serology literature and construct updated best practice guidance related to SARS-CoV-2 serologic testing. This guideline is an update to the fourth in a series of rapid, frequently updated COVID-19 guidelines developed by IDSA.
Objective: To develop evidence-based recommendations and identify unmet research needs pertaining to the use of anti-SARS-CoV-2 antibody tests for diagnosis, decisions related to vaccination and administration of monoclonal antibodies or convalescent plasma in immunocompromised patients, and identification of a serologic correlate of immunity.
Methods: A multidisciplinary panel of infectious diseases clinicians, clinical microbiologists and experts in systematic literature reviewed, identified, and prioritized clinical questions related to the use of SARS-CoV-2 serologic tests. Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the certainty of evidence and make testing recommendations.
Results: The panel recommends against serologic testing to diagnose SARS-CoV-2 infection in the first two weeks after symptom onset (strong recommendations, low certainty of evidence). Serologic testing should not be used to provide evidence of COVID-19 in symptomatic patients with a high clinical suspicion and repeatedly negative nucleic acid amplification test results (strong recommendation, very low certainty of evidence). Serologic testing may assist with the diagnosis of multisystem inflammatory syndrome in children (strong recommendation, very low certainty of evidence). To seek evidence for prior SARS-CoV-2 infection, the panel suggests testing for IgG, IgG/IgM, or total antibodies to nucleocapsid protein three to five weeks after symptom onset (conditional recommendation, low certainty of evidence). In individuals with previous SARS-CoV-2 infection or vaccination, we suggest against routine serologic testing given no demonstrated benefit to improving patient outcomes (conditional recommendation, very low certainty of evidence.) The panel acknowledges further that a negative spike antibody test may be a useful metric to identify immunocompromised patients who are candidates for immune therapy.
Conclusions: The high seroprevalence of antibodies against SARS-CoV-2 worldwide limits the utility of detecting anti-SARS CoV-2 antibody. The certainty of available evidence supporting the use of serology for diagnosis was graded as very low to low. Future studies should use serologic assays calibrated to a common reference standard.